General Information of Drug (ID: DMOG2X1)

Drug Name
Trebananib Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [1]
Renal cell carcinoma 2C90 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMOG2X1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Angiopoietin-2 (ANGPT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Faricimab DM83SEB Diabetic macular edema 9B71.02 Approved [5]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [6]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [7]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [8]
LY3127804 DMAC457 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [9]
REGN910-3 DMTBRPO Neovascular age-related macular degeneration 9B78.3Z Phase 2 [10]
CVX-060 DM03LWZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [12]
CVX-241 DMV74JC Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
REGN-910 DMHR7D4 Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Angiopoietin-1 (ANGPT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [6]
AMG 780 DMTGZN8 Solid tumour/cancer 2A00-2F9Z Phase 1 [15]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-1 (ANGPT1) TTWNQ1T ANGP1_HUMAN Inhibitor [4]
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Inhibitor [4]

References

1 ClinicalTrials.gov (NCT01281254) AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00467025) AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
4 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
5 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Company report (Roche pipeline: July 27, 2017)
8 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
11 Clinical pipeline report, company report or official report of CovX (2011).
12 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
13 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
14 Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
15 Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.